Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus propofol for deep sedation during endoscopic ultrasound procedures
2025-521784-12-00Phase 4Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in gastric cancer (GC) and pancreatic cancer (PC) comparing Remimazolam arm with Propofol arm (2 arms). Primary endpoints: Composite cardiorespiratory adverse events, Oxygen desaturation and 5 more. Planned start Jun 2026; status: authorised.
02
Drugs
remimazolampropofol
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2025-521784-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521784-12-00.